不同人群抗HBV治疗的时机和药物选择  

Anti-HBV therapy timing and drug selection in various populations

作　　者：张烨琼[1] 罗秋敏[1] 王璐 彭亮[1] 高志良[1] ZHANG Yeqiong;LUO Qiumin;WANG Lu;PENG Liang;GAO Zhiliang(Department of infectious Diseases,Third Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510630,China;Second School of Clinical Medicine,Binzhou Medical University,Yantai,Shandong 264003,China)

机构地区：[1]中山大学附属第三医院感染性疾病科,广州510630 [2]滨州医学院第二临床医学院,山东烟台264003

出　　处：《临床肝胆病杂志》2022年第11期2444-2447,共4页Journal of Clinical Hepatology

摘　　要：HBV感染仍是威胁人类健康的重大疾病,抗HBV治疗是极其重要的减少乙型肝炎威胁的手段。近年来,关于抗HBV治疗的时机以及药物选择仍无统一的意见。本文就不同人群抗HBV治疗的时机和药物的选择进行了综述。Hepatitis B virus(HBV)infection is still a serious disease threatening human health.Anti-HBV treatment is an extremely important means to reduce the threat of hepatitis B.In recent years,there has been no consensus on the timing and drug selection of anti-HBV therapy.The timing and drug selection of anti-HBV therapy in various populations are discussed in this article.

关 键 词：乙型肝炎病毒 乙型肝炎 慢性 抗病毒药 

分 类 号：R512.62[医药卫生—内科学]